We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 42% below its sector, cheaper than its peers on earnings.
Humanwell Healthcare (Group) Co.,Ltd. operates internationally, delivering a wide spectrum of healthcare solutions across regions including the Asia Pacific, North America, and Africa. The company's diverse product range features pharmaceuticals for pain management, such as anesthetics and analgesics, alongside a significant focus on women's health, providing items for reproductive planning, emergency contraception, and general wellness. They also produce central nervous system (CNS) medications addressing conditions like bronchitis, migraines, dysmenorrhea, neuralgia, epilepsy, acute and chronic cerebrovascular diseases, brain injuries, and peripheral vascular disorders. Furthermore, their offerings extend to traditional herbal remedies for common ailments such as colds and flu, rheumatoid arthritis, dermatological concerns, hepatitis, urinary tract infections, and memory impairment. Humanwell also supplies anti-infective agents, a variety of over-the-counter (OTC) drugs for digestive complaints, cold and flu relief, anti-inflammatory purposes, infections, and nutritional supplements. Complementing these, they offer specific treatments aimed at cardiovascular, gastrointestinal, and reproductive system diseases. Established in Wuhan, China, in 1993, the enterprise was initially known as Wuhan Humanwell Healthcare (Group) Co., Ltd. before adopting its current name, Humanwell Healthcare (Group) Co.,Ltd., in March 2013.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 600079.SS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
